an essential contribution to the development of health research
Innovation that changes patients’ lives!
Ms. Marie-Claude-Paré, President and CEO of the Fondation du CHU de Québec, says she is proud of this model, designed and produced from scratch by her team, in collaboration with the board of directors of the CHU de Québec-Université Laval Research Center, in order to meet the real needs of researchers. “Research is at the heart of the Foundation’s mission and our mission and our Chairs fully adhere to it. This attractive model will allow the Foundation to create new leading partnerships and attract philanthropists from all sectors who will join us to advance these Chairs. and give these researchers the means to continue their work. It’s a whole new way to make a tangible contribution to health. Research projects supported by Hospital Research Chairs are subject to a well-defined selection process, are evaluated by an external committee and approved by the boards of directors of the Research Centers. These projects should help increase patient survival rates, improve their quality of life, allow less invasive treatment options, that is to say essentially humanize the care provided at the CHU.
“These Hospital Research Chairs represent a privileged opportunity to promote the CRCHU and highlight the talent of our researchers. Funding research is a constant challenge, and this commitment from the Foundation and its donors is an essential contribution, ”confirms Mr. Serge Rivest, doctor in neurosciences, director of the CHU de Québec-Université Laval research center. In fact, the Foundation has announced an investment of $ 750,000 per chair over the next few years to ensure the continuity of large-scale research projects underway and wishes to join forces with generous, visionary and daring partners who, like the Foundation, dare to think big and want to reinvent the world. For Mr. Martin Beaumont, Director General of the CHU de Québec-Université Laval, this investment by the Foundation is undeniably an added value to the development of research carried out at the CHU. “These Hospital Research Chairs consolidate the synergy between the Foundation, the CHU and its Research Center. This is an extremely key project, with important implications for Quebec city, everything is Quebec, and beyond. We can not help but rejoice for the good of the patients! “.
A first chair in theranostics to revolutionize cancer treatment
Theranostics is an innovative treatment that combines radiosotopy and fine diagnostic imaging. It is rapidly emerging for the targeted treatment of cancer, particularly prostate cancer. Dr. Jean-Mathieu Beauregard, clinical researcher and specialist in nuclear medicine, has developed a unique and personalized approach to theranostics in which each treatment is adjusted according to the characteristics of the patient. This approach has been the subject of conclusive clinical trials which have opened the door to further studies evaluating a new therapeutic radioisotope with great promise for treating a wider variety of cancers.
Given that the fight against cancer is one of the Foundation’s priorities and that the Research Center has already proven itself in the field of theranostics, both nationally and internationally, the choice of Dr. Beauregard’s project was quite appropriate. Dr Beauregard expressed his appreciation. “I am touched by the confidence that the CHU de Québec Foundation and the Research Center have placed in me by choosing me to occupy the first Hospital Research Chairs of the Foundation. This support gives me the financial means to concentrate on my work, for the good of my patients, and it is a great relief! “.
Tangible benefits for patients
It is as part of the clinical trials conducted by Dr. Beauregard that Mr. Marco labrie became one of the first patients to have benefited from theranostic treatments at the CHU. The cancer from which he had suffered for several years affected him more and more, and the innovative approach changed everything: it extended his life, literally, and also allowed him to enjoy a better quality of life. The Hospital Research Chairs in Theranostics stem from this clinical study, allowing Dr. Beauregard to significantly advance the work and, ultimately, save more lives like Mr. Labrie’s.
Let us recall here that for many years, Mr. Labrie has partnered with the Foundation through an imaginative initiative, Concert for life, a service he organizes to financially support clinical oncology research at the CHU. The funds raised during the next editions of Concert for life will be devoted to hospital research chairs in theranostics.
To see Mr. Marco labrie, or to view the announcement of the Fondation du CHU de Québec, please contact Ms. Josée Bourassa at [email protected].
* Hospital research chairs
SOURCE Foundation of the CHU de Québec
For further information: Amélie Deschênes, Corporate Communications and Relations Advisor, CHU de Québec Foundation, [email protected], Cell: 418 805-6463